According to GlaxoSmithKline Pharmaceuticals latest financial reports the cash on hand of GLAXO is $213.78M, an decrease of -38.27% to 2022. At the end of 2022 company had $346.33M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $213.78M | -38.27% |
2022 | $346.33M | 149.61% |
2021 | $138.75M | 9.52% |
2020 | $126.69M | -7.49% |
2019 | $136.94M | - |